In March, FDA commissioner Scott Gottlieb announced his resignation, which became effective last Friday, April 5th. Highly regarded by life ...

Clinical trials have long been viewed as complicated and high-volume endeavors, involving the widespread recruitment of patients, supply chain planning ...

Over half of US states have proposed new drug pricing laws and transparency legislation in the past two to three ...

As the U.S. continues to face the government shutdown in 2019, the longest in history, the lack of funding for ...

The 2019 pharmaceutical trends build off an exciting 2018 in pharma with new developments in artificial intelligence, R&D, personalized medicine, ...

“The right dose of the right medicine delivered to the right patient at the right time…and at the right cost”.  ...

Over the last two years, discussions about the applications of AI have broken through the mainstream and reached a level ...

Artificial intelligence is here. AI-driven capabilities that not too long ago may have seemed like science fiction are now being ...

The meticulous art of R&D demands extensive collaboration, mastery of technical skills, and scientific acumen. In and of itself, the ...

For pharmaceutical and biotechnology companies focusing on research and development, prioritizing data transparency and clinical study reporting (CSR) is a ...

Day after day, headline after headline, blockchain is referenced as a solution for an array of complex challenges facing businesses ...

The advent of personalized medicine is a result of countless innovations in an array of fields, including genomic sequencing, big ...